Skip to Content

Melflufen is Safe and Effective in Patients with Alkylator-Refractory Disease

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years.

Fredrik Hellem Schjesvold

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top